Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

HIV Clinical Trial

Official title:

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01969461
• Other study ID #: 1R01AA022891-01
• Status: Recruiting
• Phase: N/A
• First received: October 17, 2013
• Last updated: January 6, 2017
• Start date: July 2014
• Est. completion date: December 2018

Study information

• Verified date: January 2017
• Source: Wayne State University
• Contact: Sylvie Naar-King, PhD
• Phone: 3137454875
• Email: snaarkin[@]med.wayne.edu
• Is FDA regulated: No
• Health authority: United States: Data and Safety Monitoring BoardUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Alcohol use among persons with HIV exacerbates health problems and accelerates HIV disease progression. Antiretroviral therapy (ART) is the single most important treatment for people living with HIV. However, ART adherence is suboptimal among adolescents and young adults living with HIV, the age group with the fastest growing rates of HIV infection, and great risk of engaging in risky behaviors such as alcohol use. The proposed study will compare the effectiveness of home-based versus clinic-based "Healthy Choices", a brief, 4- session intervention using Motivational Enhancement Therapy (MET) to address alcohol use, medication adherence, and health outcomes in youth living with HIV (YLH) using a repeated measures design. Unlike previous trials, Healthy Choices will be tested in a "real world" clinical setting and be delivered by community health workers (CHW: already members of the HIV care team). The study population will consist of YLH, ages 16-24, who are current patients at 5 ATN sites. Site staff will recruit potential participants. Youth will be randomized to receive Healthy Choices, either clinic-based or home-based delivered by the same CHW in both conditions. Outcomes are measured at baseline, 4-, 7-, and 13-months. Data collection for biological measures will be through medical record extraction, and self-reported measures will occur using a brief Web-based CASI (computer-administered self-interviewing) survey on an iPad. All intervention sessions will be audio-recorded for MITI fidelity coding, and investigators will support local supervisors during the active intervention phase. We will conduct qualitative interviews with CHWs, supervisors and organization leaders at the end of the trial to obtain information about barriers and facilitators of implementation. Thus, the proposed trial will allow us to use a Type 1 Effectiveness-implementation hybrid design to pilot a sustainable model of MI implementation in real-world youth care settings towards the goals of 1) examining the effectiveness, cost-effectiveness, and scalability of an efficacious behavioral intervention when delivered by CHWs in real-world adolescent HIV care settings; 2) gathering information about who responds under what contexts; and 3) increasing our understanding of the barriers and facilitators for future implementation. The primary hypothesis is that YLH receiving home-based MET will have greater improvements in alcohol use and viral load than YLH receiving clinic-based MET.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 24 Years

Eligibility

Inclusion Criteria:

• HIV-infected

• Ability to speak and understand English

• Prescribed antiretroviral therapy

• Detectable viral load in the last month

Exclusion Criteria:

• Not fluent in English

• History of sever learning disability, mental retardation, major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depression with psychotic features, etc).

• Participation in another adherence intervention trial

• On ART due to pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV

Intervention

Behavioral:
• Motivational Enhancement Therapy (MET)
The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.

Locations

Country	Name	City	State
United States	Adolescent Trials Network (ATN) Sites	Birmingham	Alabama

Sponsors (8)

Lead Sponsor	Collaborator
Wayne State University	City University of New York, School of Public Health, Columbia University, Medical University of South Carolina, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Diego, Westat

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Barriers and Facilitators of the MI Implementation Process	The qualitative interview guide (with input from Dr. Norton, consultant) will focus on barriers and facilitators of implementation experienced at the individual, clinic, protocol team, and organizational level. Both positive and potentially negative outcomes will be elicited. Interviews will be conducted at the end of the MET intervention phase to assess sustainability.	4 months post baseline	No
Other	Barriers and Facilitators of the MI Implementation Process	The qualitative interview guide (with input from Dr. Norton, consultant) will focus on barriers and facilitators of implementation experienced at the individual, clinic, protocol team, and organizational level. Both positive and potentially negative outcomes will be elicited. Interviews will be conducted at the end of the trial to assess sustainability.	13 months post Baseline	No
Primary	Change in Alcohol Use from Baseline to 9 months post intervention	We will use multiple methods of assessing use including calendar-based interview, biomarker, and self-report questionnaire.	Baseline, 4-, 7-, and 13-months	No
Primary	Change in Viral Load from Baseline to 9 months post intervention	Viral load will be extracted from medical records, though we have budgeted to collect a percentage of viral loads for youth who drop out of care or transfer to a care setting where records are not available.	Baseline, 4-, 7-, and 13-months	No
Secondary	Change in Medication Adherence from Baseline to 9 months post intervention	We will use self-report and interviews that have been successful in our previous trials.	Baseline, 4-, 7-, and 13-months	No
Secondary	Change in Sexual Risk from Baseline to 9 months post intervention	We will use self-report and interviews that have been successful in our previous trials.	Baseline, 4-, 7-, and 13-months	No
Secondary	Change in Other Substance Use (not alcohol use) from Baseline to 9 months post intervention	Objective measures are cost prohibitive (e.g., MEMS, hair assays, STI tests, urine screens) for these secondary outcomes; thus we will use self-report and interviews that have been successful in our previous trials.	Baseline, 4-, 7-, and 13-months	No